14 June 2004
Munich, Germany; Hamburg, Germany; Oxfordshire, UK – Neuronova AG (private) and Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced that they have entered into a drug discovery agreement to identify small molecule compounds that interact with a Neuronova target involved in the treatment of depression and anxiety.
In the search for novel compounds, Evotec OAI will apply its world-class capabilities in the areas of cell-line construction, assay development and screening on a complex cellular target. In addition, Evotec OAI will provide profiling services to Neuronova to further characterise selected hits for progression.
Bernard Questier, Chief Business Officer of Evotec OAI, said: “We are proud that Neuronova has selected Evotec OAI as their partner of choice to identify novel structures to progress towards the clinic. Our integrated discovery capabilities ideally complement Neuronova’s extensive disease biology expertise in behavioural pharmacology and we are convinced that we will add significant value to their drug discovery programme.”
Dr Herbert Stadler, Chief Executive Officer of Neuronova AG, commented: “By choosing Evotec OAI as solutions provider for the identification of drug candidates we are ideally positioned to speed up the development of our pipeline based on proprietary targets in affective disorders. Our development candidates have significant potential to provide new treatment options which are faster acting and have less side effects than current therapies.”
Contact for Neuronova AG:
Herbert Stadler
Chief Executive Officer
Kraepelinstraße 2
D-80804 Munich
Tel.: +49.(0).89.30622-591
Fax: +49.(0).89.30622-370
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Contact for Evotec OAI AG:
Bernard Questier
Chief Business Officer
Schnackenburgallee 114
D-22525 Hamburg
Tel.: +49.(0).40.56081-434
Fax: +49.(0).40.56081-333
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
| File | File size |
|---|---|
 2004-06 Affectis - Evotec engl.pdf | 56 Kb |
Copyright © 2012 Affectis Pharmaceuticals AG. All Rights Reserved.
